Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners

Fineline Cube Jun 22, 2026
Company Deals

Insilico Medicine and SK Biopharmaceuticals Launch $2.5B AI Drug Discovery Collaboration Targeting Neuroimmune Diseases

Fineline Cube Jun 22, 2026
Company Deals

UCB Completes $2.2B Acquisition of Candid Therapeutics to Advance BCMA T-Cell Engager for Autoimmune Diseases

Fineline Cube Jun 18, 2026
Company Deals

Eli Lilly Acquires 4E Therapeutics to Advance Next-Generation Chronic Pain Pipeline

Fineline Cube Jun 18, 2026
Company Deals

Xunfei Healthcare Partners with Sinar Mas Group to Deploy AI Medical Solutions Across Indonesia

Fineline Cube Jun 18, 2026
Policy / Regulatory

NMPA Releases 106th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Including BeOne Medicines’ Brukinsa (zanubrutinib)

Fineline Cube Jun 17, 2026
Company Drug

IASO Biotherapeutics’ Fucaso Becomes First BCMA CAR-T Therapy Approved in Singapore for Relapsed/Refractory Multiple Myeloma

Fineline Cube Jun 22, 2026
Company Drug

Sanofi’s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings

Fineline Cube Jun 22, 2026
Company Deals

Mindray Partners with Vazyme Biotech to Develop Automated Infection Screening Solutions

Fineline Cube May 30, 2023

China-based medical device company Mindray (SHE: 300760) has entered into a partnership with fellow Chinese...

Company Drug

Hisun Pharmaceutical’s SHP2 Inhibitor HS336 Gets NMPA Clinical Trial Approval

Fineline Cube May 30, 2023

Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267), a China-based pharmaceutical company, has announced that it...

Policy / Regulatory

Hainan Boao Lecheng Introduces 319 Overseas Drugs and Devices, Reports Significant Growth

Fineline Cube May 30, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has introduced 319 clinically urgently needed...

Company

Moderna Establishes USD 100 Million Subsidiary in Shanghai to Expand mRNA Technology

Fineline Cube May 29, 2023

US-based vaccine manufacturer Moderna (NASDAQ: MRNA) has registered a new subsidiary in the Minhang district...

Drug Policy / Regulatory

Hubei Leads National Volume-Based Procurement of Patented Traditional Chinese Medicines

Fineline Cube May 29, 2023

The Healthcare Security Administration (HSA) bureau of Hubei province has released a notification outlining plans...

Company Drug

Harbour Biomed’s Porustobart Combo Shows Promise in HCC Treatment, ASCO Presentation Reveals

Fineline Cube May 29, 2023

China-based Harbour Biomed (HKG: 2142) has announced the publication of results from a Phase Ib...

Company Drug

Ascentage Pharma’s Olverembatinib Earns Breakthrough Designation for SDH-Deficient GIST

Fineline Cube May 29, 2023

The China’s Center for Drug Evaluation (CDE) has granted breakthrough therapy designation (BTD) to olverembatinib,...

Company Drug

Abbisko Therapeutics Reports Positive Phase Ib Results for ABSK021 at ASCO

Fineline Cube May 29, 2023

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) is poised to announce positive results from...

Company Drug

Shanghai Yizhong’s Paclitaxel Micelles Data to be Presented at ASCO Annual Meeting

Fineline Cube May 29, 2023

Shanghai Yizhong Pharmaceutical Co., Ltd (SHA: 688091), a China-based pharmaceutical company, has announced that clinical...

Legal / IP

SAMR Imposes Penalties on Grand Pharma and WuHan Huihai for Monopoly Agreements

Fineline Cube May 29, 2023

The State Administration for Market Regulation (SAMR) has imposed administrative penalties on Grand Pharmaceutical Group...

Company Drug

Ascentage Pharma to Present Clinical Results of Four Oncology Drugs at Medical Conference

Fineline Cube May 29, 2023

Suzhou-based Ascentage Pharma (HKG: 6855) has announced its intention to present the clinical results of...

Deals Policy / Regulatory

Hainan Province and NHSA Partner to Enhance Medical Insurance Industry with Real-World Data

Fineline Cube May 26, 2023

The government of Hainan province has entered into a strategic partnership with the National Healthcare...

Company Drug

BeiGene Presents Groundbreaking Clinical Data at ASCO Annual Meeting

Fineline Cube May 26, 2023

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced the presentation of new data at...

Policy / Regulatory

Shanghai Market Regulation Bureau Targets Unfair Competition in Pharmaceutical Sector

Fineline Cube May 26, 2023

The Shanghai market regulation bureau has released a document aimed at cracking down on unfair...

Company Deals

TianLong Science and Technology Expands into Northern Thailand with Hepatitis Diagnostics

Fineline Cube May 26, 2023

Xi’an-based med-tech firm TianLong Science and Technology Co., Ltd has reportedly entered into a supply...

Company Drug

Chia Tai Tianqing’s TQ-B3525 Heads for Priority Review for Recurrent Follicular Lymphoma

Fineline Cube May 26, 2023

The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQ-B3525, a...

Company Drug

Sanofi Launches Soliqua for Type 2 Diabetes Treatment in China

Fineline Cube May 26, 2023

French pharmaceutical major Sanofi (NASDAQ: SNY) has announced the official market launch of Soliqua (insulin...

Company Drug

GenScript’s Legend Biotech Files Type II Variation Application for Carvykti with EMA

Fineline Cube May 26, 2023

China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary,...

Company Drug

Takeda and HutchMed’s Fruquintinib Receives Priority Review Status from FDA

Fineline Cube May 26, 2023

Takeda (TYO: 4502) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) have provided an update...

Policy / Regulatory

China’s NHC Releases Fourth List of Pediatric Priority Drugs to Boost Development

Fineline Cube May 26, 2023

The National Health Commission (NHC) of China has published its fourth list of pediatric drugs...

Posts pagination

1 … 541 542 543 … 686

Recent updates

  • Jenscare’s Ken-Valve TAVR System Gains Hong Kong Approval for Aortic Regurgitation Following Mainland China Launch
  • IASO Biotherapeutics’ Fucaso Becomes First BCMA CAR-T Therapy Approved in Singapore for Relapsed/Refractory Multiple Myeloma
  • Sanofi’s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings
  • Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners
  • Roche’s Lunsumio-Polatuzumab Combination Accepted for FDA Review in Relapsed/Refractory Large B-Cell Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Jenscare’s Ken-Valve TAVR System Gains Hong Kong Approval for Aortic Regurgitation Following Mainland China Launch

Company Drug

IASO Biotherapeutics’ Fucaso Becomes First BCMA CAR-T Therapy Approved in Singapore for Relapsed/Refractory Multiple Myeloma

Company Drug

Sanofi’s Sarclisa Subcutaneous Formulation Approved in Japan for Multiple Myeloma Across Treatment Settings

Company Deals

Dawnrays Pharmaceutical Launches RMB 200 Million Biopharma Venture Fund with Shanghai Jianxin Partners

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.